Compare Equinor ASA (EQNR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Vertex Pharmaceuticals Incorporated — how do they compare? Equinor ASA trades at $42.72 (market cap $100.03B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Equinor ASA pays a 3.75% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EQNR | VRTX | |
|---|---|---|
Market Cap | $100.03B | $128.16B |
Volume | 4,457,638 | 806,603 |
Sector | Energy | Health |
52-Week High | $45.75 | $557.96 |
52-Week Low | $22.41 | $407.37 |
Typical Hold Time | 59 Days | 120 Days |
Enterprise Value | $108.72B | $122.29B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $42.93, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The stock presents compelling value with a P/E of 11.28 and EV/EBITDA of 2.35, well below industry averages. Recent developments include expansion in LNG operations and carbon capture projects, while maintaining strong operational cash flow of $20B. The company continues shareholder returns through dividends and buybacks.
EQNR offers significant upside potential with a consensus price target of $70.50 representing 64% upside, supported by improving earnings outlook and strategic LNG expansion. Key risks include volatile energy prices and execution challenges in new projects. Analyst sentiment is mixed with 30% buy ratings, but recent Zacks upgrades to Strong Buy highlight growing optimism about earnings recovery through 2026.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
